Title:
AbCellera COVID-19 Project
Agreement Value:
$175,631,000.00
Agreement Date:
Mar 23, 2020 - Mar 31, 2024
Description:
The project is in direct response to Canada's fight against COVID-19 and Canada's ability to respond to future pandemics. It will enable the rapid discovery of antibody therapies to treat and prevent COVID-19 and establish a Good Manufacturing Practice antibody production facility for Canada's long-term emergency preparedness.
Organization:
Innovation, Science and Economic Development Canada
Expected Results:
This investment will allow the company to improve its antibody discovery platform by incorporating advanced technologies such as artificial intelligence and machine learning to optimize the quality and speed of discovering antibodies with the strongest potential for a COVID-19 therapeutic antibody, helping improve Canada's ability to respond to future pandemics.
Location:
Vancouver, British Columbia, CA V5Y0A1
Reference Number:
033-2020-2021-Q1-512889
Agreement Type:
Other transfer payment
Report Type:
Grants and Contributions
Recipient Business Number:
838509446
Recipient Type:
For-profit organization
Additional Information:
This type of agreement is a partially repayable contribution.
Recipient's Operating Name:
AbCellera Biologics Inc.
Recipient's Legal Name:
AbCellera Biologics Inc.
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
SIF Stream2- Growth
Program Purpose:
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.